Published in Hepatology · View the paper (DOI)
Researchers have identified specific resistance mutations in the p7 protein that may explain the lack of effectiveness of current p7 inhibitor drugs. The study supports the use of combination therapies inhibiting p7 as a potential component of future HCV-specific treatments, offering new hope for effective therapies.
Coverage from 2 institutions